NCT05111431
Completed
Phase 3
Study on Efficacy and Safety of Dexmedetomidine Hydrochloride Nasal Spray for Preoperative Sedation in Children
ConditionsPreoperative Sedation of Children
Overview
- Phase
- Phase 3
- Intervention
- Dexmedetomidine Hydrochloride Nasal Spray
- Conditions
- Preoperative Sedation of Children
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Enrollment
- 159
- Locations
- 1
- Primary Endpoint
- Proportion of subjects who meet parent-child separation successful
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
The study is being conducted to evaluate the efficacy, and safety of dexmedetomidine hydrochloride nasal spray for preoperative sedation in children.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Able and willing to provide a written informed consent
- •Male or female
- •Subjects requiring elective general anesthesia surgery
- •Conform to the ASA Physical Status Classification
- •Meet the weight standard
Exclusion Criteria
- •Not suitable for nasal spray
- •Pediatric populations requiring special care or court/social welfare supervision
- •Subjects who had been under general anesthesia when they were randomized
- •Subjects with a history of mental illness and a history of cognitive impairment epilepsy
- •Subjects with cardiovascular disease
- •Subjects whose hemoglobin is below the lower limit of normal
- •Subjects with a history or possibility of a difficult airway
- •Abnormal liver function and/or abnormal renal function
- •Adrenoceptor agonists or antagonists or analgesics were used before randomization
- •Participated in clinical trials (received experimental drugs)
Arms & Interventions
Dexmedetomidine Hydrochloride Nasal Spray
Intervention: Dexmedetomidine Hydrochloride Nasal Spray
Dexmedetomidine hydrochloride nasal spray blank preparation
Intervention: Dexmedetomidine hydrochloride nasal spray blank preparation
Outcomes
Primary Outcomes
Proportion of subjects who meet parent-child separation successful
Time Frame: within 45 minutes after the beginning of administration
Proportion of subjects who meet the Ramsay sedation score of 3 at least once within 45 minutes after the beginning of administration
Time Frame: within 45 minutes after the beginning of administration
Secondary Outcomes
- Proportion of subjects who meet parent-child separation successful within 45 minutes after the beginning of administration(Within 45 minutes after the beginning of administration)
- Time from the beginning of administration to the successful parent-child separation for the first time through study completion,an average of 3 days(an average of 3 days)
- Proportion of subjects whose the Ramsay score is satisfactory at least once within 45 minutes after the beginning of administration(Within 45 minutes after the beginning of administration)
- Time from the beginning of administration to the satisfactory Ramsay score for the first time(from the beginning of administration to the first successful Ramsay score)
- Proportion of subjects whose the UMSS Scale is satisfactory at least once within 45 minutes after the beginning of administration(within 45 minutes after the beginning of administration)
- Time from the beginning of administration to the satisfactory UMSS score for the first time through study completion,an average of 3 days(an average of 3 days)
- Time of anesthesia awakening through study completion,an average of 3 days(an average of 3 days)
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Phase 2
A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of AdultsPreoperative SedationNCT04383418Jiangsu HengRui Medicine Co., Ltd.201
Terminated
Not Applicable
Dexmedetomidine and Fentanyl Versus Midazolam and Remifentanil for Sedation in Patients Undergoing Ablation ProceduresTachyarrhythmiaNCT03451227University Health Network, Toronto6
Not yet recruiting
Phase 3
To study and compare the analgesic effect of Dexmedetomidine with Levobupivacaine, Ropivacaine and Bupivacaine under spinal anesthesia.Health Condition 1: O- Medical and SurgicalCTRI/2023/06/054099Department of Anaesthesia and Critical Care
Recruiting
Phase 1
A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer PatientsAdvanced Unresectable or Metastatic Breast CancerNCT06679036Shandong Suncadia Medicine Co., Ltd.300
Completed
Phase 2
Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational AgeAnesthesiaNCT01508455Hospira, now a wholly owned subsidiary of Pfizer6